How PCR Powers BioFire Syndromic Testing
The BioFire System runs syndromic infectious disease diagnostic tests, which use multiplex PCR technology to isolate, amplify, and detect the nucleic acid of targeted microorganisms. Results from a BioFire diagnostic test are fast, accurate, and comprehensive, helping healthcare providers improve patient management.
PCR is more relevant than ever with the widespread use of PCR-based COVID-19 tests, including the FDA De Novo authorized BioFire® Respiratory 2.1 Panel, which tests for SARS-CoV-2 and 21 other respiratory pathogens. The BioFire RP2.1 Panel and other syndromic panels that run on the BioFire System have provided a much-needed diagnostic solution not only for the pandemic, but for respiratory seasons to come. Without Thomas Brock’s groundbreaking discovery of Thermus aquaticus and the subsequent invention of PCR, our syndromic testing work here at BioFire would not be possible.